3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
Dexamethasone
5
Trimethoprim, Sulfamethoxazole Drug Combination
4
gamma-Globulins
3
Lenalidomide
3
Ciprofloxacin
3
Bortezomib
3
pomalidomide
2
fludarabine phosphate
2
fludarabine
2
elotuzumab
2
carfilzomib
2
Radiotherapy
2
Immunoglobulins, Intravenous
2
Cyclophosphamide
2
Amoxicillin-Potassium Clavulanate Combination
2
siltuximab
1
selinexor
1
nirogacestat
1
iberdomide
1
daratumumab
1
belantamab mafodotin
1
Positron-Emission Tomography
1
Melphalan
1
Interviews as Topic
1
Immunoglobulins
1
Focus Groups
1
Fecal Microbiota Transplantation
1
Clonal Hematopoiesis
1
Clavulanic Acid
1
Chromatin Immunoprecipitation Sequencing
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms, Plasma Cell
×
Clavulanic Acid
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled